PEG: Net loss narrowed as clinical progress and a key legal win improved financial position, but funding needs persist
قراءة أقل من دقيقة
Reponex advanced clinical programs and strengthened its IP portfolio, while an arbitral award improved the outlook for recovering the Portinho S.A. receivable. The group reported a reduced net loss and improved equity, but remains pre-revenue and reliant on further financing and licensing deals.
Original document: Pharma Equity Group A/S Class A [PEG] Interim report — Aug. 14 2026
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
© AI-generated summary is provided by Quartr